Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $16.0 million.

  • Inhibrx Biosciences' Non-Current Assets rose 616.57% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.8 million, marking a year-over-year change of. This contributed to the annual value of $20.4 million for FY2024, which is 6249.7% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Non-Current Assets stood at $16.0 million for Q3 2025, which was up 616.57% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Non-Current Assets ranged from a high of $20.4 million in Q4 2024 and a low of $12.5 million during Q4 2023
  • Moreover, its 3-year median value for Non-Current Assets was $16.4 million (2024), whereas its average is $16.8 million.
  • Per our database at Business Quant, Inhibrx Biosciences' Non-Current Assets soared by 6249.7% in 2024 and then skyrocketed by 616.57% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Non-Current Assets (Quarter) stood at $12.5 million in 2023, then soared by 62.5% to $20.4 million in 2024, then fell by 21.21% to $16.0 million in 2025.
  • Its Non-Current Assets was $16.0 million in Q3 2025, compared to $18.2 million in Q2 2025 and $19.3 million in Q1 2025.